Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1

English version České info

Approximately 80% of human breast carcinomas present as oestrogen receptor α-positive (ER+ve) disease, and ER status is a critical factor in treatment decision-making. Recently, single nucleotide polymorphisms (SNPs) in the region immediately upstream of the ER gene (ESR1) on 6q25.1 have been associated with breast cancer risk. Our investigation of factors associated with the level of expression of ESR1 in ER+ve tumours has revealed unexpected associations between genes in this region and ESR1 expression that are important to consider in studies of the genetic causes of breast cancer risk. RNA from tumour biopsies taken from 104 postmenopausal women before and after 2 weeks treatment with an aromatase (oestrogen synthase) inhibitor was analyzed on Illumina 48K microarrays. Multiple-testing corrected Spearman correlation revealed that three previously uncharacterized open reading frames (ORFs) located immediately upstream of ESR1, C6ORF96, C6ORF97, and C6ORF211 were highly correlated with ESR1 (Rs = 0.67, 0.64, and 0.55 respectively, FDR<1×10⁻⁷). Publicly available datasets confirmed this relationship in other groups of ER+ve tumours. DNA copy number changes did not account for the correlations. The correlations were maintained in cultured cells. An ERα antagonist did not affect the ORFs' expression or their correlation with ESR1, suggesting their transcriptional co-activation is not directly mediated by ERα. siRNA inhibition of C6ORF211 suppressed proliferation in MCF7 cells, and C6ORF211 positively correlated with a proliferation metagene in tumours. In contrast, C6ORF97 expression correlated negatively with the metagene and predicted for improved disease-free survival in a tamoxifen-treated published dataset, independently of ESR1. Our observations suggest that some of the biological effects previously attributed to ER could be mediated and/or modified by these co-expressed genes. The co-expression and function of these genes may be important influences on the recently identified relationship between SNPs in this region and breast cancer risk.

Vyšlo v časopise: Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1. PLoS Genet 7(4): e32767. doi:10.1371/journal.pgen.1001382
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1001382

Souhrn

Zdroje

1. ParkinDM

BrayF

FerlayJ

PisaniP

2005 Global cancer statistics, 2002. CA Cancer J Clin 55 74 108

2. DowsettM

DunbierAK

2008 Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14 8019 8026

3. PerouCM

SorlieT

EisenMB

van de RijnM

JeffreySS

2000 Molecular portraits of human breast tumours. Nature 406 747 752

4. HammesSR

LevinER

2007 Extranuclear steroid receptors: nature and actions. Endocr Rev 28 726 741

5. SorlieT

TibshiraniR

ParkerJ

HastieT

MarronJS

2003 Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 8418 8423

6. ZhengW

LongJ

GaoYT

LiC

ZhengY

2009 Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41 324 328

7. TurnbullC

AhmedS

MorrisonJ

PernetD

RenwickA

2010 Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42 504 7

8. StaceySN

SulemP

ZanonC

GudjonssonSA

ThorleifssonG

2010 Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus. PLoS Genet 6 e1001029 doi:10.1371/journal.pgen.1001029

9. FletcherO

JohnsonN

OrrN

HoskingFJ

GibsonLJ

2011 Novel Breast Cancer Susceptibility Locus at 9q31.2: Results of a Genome-Wide Association Study. J Natl Cancer Inst 103 425 35

10. CaiQ

WenW

QuS

LiG

EganKM

2011 Replication and Functional Genomic Analyses of the Breast Cancer Susceptibility Locus at 6q25.1 Generalize Its Importance in Women of Chinese, Japanese, and European Ancestry. Cancer Res 71 1344 1355

11. FrasorJ

DanesJM

KommB

ChangKC

LyttleCR

2003 Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 4562 4574

12. OhDS

TroesterMA

UsaryJ

HuZ

HeX

2006 Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24 1656 1664

13. YuJ

YuJ

CorderoKE

JohnsonMD

GhoshD

2008 A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. Neoplasia 10 79 88

14. MillerWR

LarionovAA

RenshawL

AndersonTJ

WhiteS

2007 Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics 17 813 826

15. MackayA

UrruticoecheaA

DixonJM

DexterT

FenwickK

2007 Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 9 R37

16. Mello-GrandM

SinghV

GhimentiC

ScatoliniM

RegoloL

2010 Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. Breast Cancer Res Treat

17. CarrollJS

MeyerCA

SongJ

LiW

GeistlingerTR

2006 Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38 1289 1297

18. FullwoodMJ

LiuMH

PanYF

LiuJ

XuH

2009 An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 462 58 64

19. RaeJM

JohnsonMD

ScheysJO

CorderoKE

LariosJM

2005 GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 92 141 149

20. ShangY

HuX

DiRenzoJ

LazarMA

BrownM

2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 843 852

21. MusgroveEA

SutherlandRL

2009 Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9 631 643

22. AliS

CoombesRC

2002 Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2 101 112

23. SmithIE

WalshG

SkeneA

LlombartA

MayordomoJI

2007 A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 25 3816 3822

24. WangY

KlijnJG

ZhangY

SieuwertsAM

LookMP

2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 671 679

25. HolstF

StahlPR

RuizC

HellwinkelO

JehanZ

2007 Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39 655 660

26. Reis-FilhoJS

DruryS

LambrosMB

MarchioC

JohnsonN

2008 ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40 809 810; author reply 810-802

27. MackayA

TamberN

FenwickK

IravaniM

GrigoriadisA

2009 A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 118 481 498

28. XiaW

BacusS

HegdeP

HusainI

StrumJ

2006 A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 103 7795 7800

29. LearyAF

MartinL

ThornhillA

DowsettM

JohnstonS

2010 Combining or Sequencing Targeted Therapies in ER+/HER2 Amplified Breast Cancer (BC): In Vitro and In Vivo Studies of Letrozole and Lapatinib in an ER+/HER2+ Aromatase-Transfected BC Model. Cancer Res 70 292s

30. MartinLA

FarmerI

JohnstonSR

AliS

MarshallC

2003 Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278 30458 30468

31. WakelingAE

BowlerJ

1992 ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 43 173 177

32. McClellandRA

GeeJM

FrancisAB

RobertsonJF

BlameyRW

1996 Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. Eur J Cancer 32A 413 416

33. LiGJ

ZhaoQ

ZhengW

2005 Alteration at translational but not transcriptional level of transferrin receptor expression following manganese exposure at the blood-CSF barrier in vitro. Toxicol Appl Pharmacol 205 188 200

34. GhazouiZ

BuffaFM

DunbierAK

AndersonH

DexterT

2011 Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor treated ER-positive breast cancer. Clin Cancer Res

35. LoiS

Haibe-KainsB

DesmedtC

WirapatiP

LallemandF

2008 Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9 239

36. LoiS

Haibe-KainsB

DesmedtC

LallemandF

TuttAM

2007 Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25 1239 1246

37. DruryS

JohnsonN

HillsM

SalterJ

DunbierA

2010 A breast cancer-associated SNP adjacent to ESR1 correlates with oestrogen receptor-alpha (ER alpha) level in invasive breast tumours. Cancer Res 69 4138

38. DunbierAK

AndersonH

GhazouiZ

PancholiS

SidhuK

2010 ESR1 is co-expressed with closely adjacent novel genes in estrogen receptor positive breast cancer. Presented at the 101st American Association for Cancer Research Annual Meeting, Washington DC, USA Abstract number 2916

39. LazennecG

HuignardH

ValotaireY

KernL

1995 Characterization of the transcription start point of the trout estrogen receptor-encoding gene: evidence for alternative splicing in the 5′ untranslated region. Gene 166 243 247

40. MartinMB

SacedaM

Garcia-MoralesP

GottardisMM

1994 Regulation of estrogen receptor expression. Breast Cancer Res Treat 31 183 189

41. MartinMB

AngeloniSV

Garcia-MoralesP

ShollerPF

Castro-GalacheMD

2004 Regulation of estrogen receptor-alpha expression in MCF-7 cells by taxol. J Endocrinol 180 487 496

42. AngeloniSV

MartinMB

Garcia-MoralesP

Castro-GalacheMD

FerragutJA

2004 Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol 180 497 504

43. Lieberman-AidenE

van BerkumNL

WilliamsL

ImakaevM

RagoczyT

2009 Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 326 289 293

44. http://www.genecards.org/

45. http://www.ncbi.nlm.nih.gov/homologene

46. EwingRM

ChuP

ElismaF

LiH

TaylorP

2007 Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol 3 89

47. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 1451 1467

48. The World Medical Association: Declaration of Helsinki. http://www.wma.net/e/policy/b3htm

49. DuP

KibbeWA

LinSM

2008 lumi: a pipeline for processing Illumina microarray. Bioinformatics 24 1547 1548

50. KornEL

TroendleJF

McShaneLM

SimonR

2004 Controlling the number of false discoveries: application to high-dimensional genomic data. Journal of Statistical Planning and Inference 124 379 398

51. MillerLD

SmedsJ

GeorgeJ

VegaVB

VergaraL

2005 An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102 13550 13555

52. DesmedtC

PietteF

LoiS

WangY

LallemandF

2007 Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13 3207 3214

53. HuangF

ReevesK

HanX

FairchildC

PlateroS

2007 Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67 2226 2238

54. GhazouiZ

BuffaFM

DunbierAK

AndersonH

DexterT

2009 Aromatase Inhibitors Reduce the Expression of a Hypoxia Metagene in Oestrogen Receptor Positive Breast Cancer in Postmenopausal Women. Cancer Res 69 408

55. MarchioC

IravaniM

NatrajanR

LambrosMB

SavageK

2008 Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 215 398 410

56. NatrajanR

WeigeltB

MackayA

GeyerFC

GrigoriadisA

2010 An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 121 575 589

57. DruryS

AndersonH

DowsettM

2009 Selection of REFERENCE genes for normalization of qRT-PCR data derived from FFPE breast tumors. Diagn Mol Pathol 18 103 107

58. PancholiS

LykkesfeldtAE

HilmiC

BanerjeeS

LearyA

2008 ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer 15 985 1002

59. DarbreP

YatesJ

CurtisS

KingRJ

1983 Effect of estradiol on human breast cancer cells in culture. Cancer Res 43 349 354